Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.

from Reuters: Business News http://ift.tt/2BiQNJT